Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for weight reduction in clozapine-treated adults with schizophrenia-spectrum disorders
ACTRN12621001539820Phase 2Terminated
- Sponsor
- The University of Queensland
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in obesity and cardiometabolic risk (CMR) comparing Semaglutide + routine care with Placebo + routine care (2 arms). Primary endpoint: Change in body weight. Started Aug 2022; status: terminated.
02
Drugs
03
Conditions
obesitycardiometabolic risk (CMR)
Beyond the preview
Go deeper on ACTRN12621001539820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001539820.